PAVM · PAVmed Inc.
$5.04
+0.00 (+0.00%)
At close · Aug 5
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying consolidated financial statements are issued.”View the 10-Q filed May 14, 2026
Market Cap
$36.65M
Shares
7.27M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Lishan Aklog | CEO | $1,365,200 |
| Michael A. Gordon | General Counsel | $1,122,950 |
| Dennis McGrath | CFO | $1,085,950 |
| Shaun M. O’Neil | COO | $1,047,950 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Lishan Aklog | CEO | $953,200 |
| Michael A. Gordon | General Counsel | $710,500 |
| Dennis McGrath | CFO | $673,500 |
| Shaun M. O’Neil | COO | $498,000 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lishan Aklog | CEO | $1,634,791 |
| Shaun M. O’Neil | COO | $1,439,874 |
| Dennis McGrath | CFO | $1,233,075 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Lishan Aklog | CEO | $9,261,677 |
| Dennis McGrath | CFO | $8,621,860 |
| Brian J. deGuzman | Chief Technology and Compliance Officer | $593,100 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lishan Aklog | CEO | $1,196,300 |
| Dennis McGrath | CFO | $1,027,700 |
| Brian J. deGuzman | Chief Technology and Compliance Officer | $490,700 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Dennis McGrath | CFO | $1,047,500 |
| Lishan Aklog | CEO | $889,850 |
| Brian J. deGuzman | Chief Technology and Compliance Officer | $503,033 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael J. Glennon | Class C director | Appointed | 2025-06-18 |
| Lishan Aklog, M.D. | Class C director | Appointed | 2025-06-18 |